{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"50% reduction in prolactin level measured monthly on 6 months therapy compared to baseline level.","groups":[{"description":"All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study.\n\nLapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.","id":"OG000","title":"Lapatinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"There were 6 prolactinomas and 3 nonfunctioning tumors in this trial. Prolactin results are only reported for the prolactinomas.","reportingStatus":"POSTED","timeFrame":"every month, up to 6 months","title":"Number of Participants With 50% Reduction in Prolactin Levels","type":"PRIMARY","unitOfMeasure":"Participants"}